Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors.
作者信息
Wagner Kay-Uwe
机构信息
Department of Oncology, School of Medicine and Tumor Biology Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code EL01TM, Detroit, MI, 48201, USA.
出版信息
Breast Cancer Res. 2022 Jun 27;24(1):44. doi: 10.1186/s13058-022-01538-8.
Abstract
摘要
相似文献
1
Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors.了解你的细胞：常用的三阴性人乳腺癌细胞系携带RAS及效应器突变。
Breast Cancer Res. 2022 Jun 27;24(1):44. doi: 10.1186/s13058-022-01538-8.
2
Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.三阴性乳腺癌和遗传性非三阴性乳腺癌患者中参与同源重组DNA损伤修复的基因的种系突变患病率
PLoS One. 2015 Jun 17;10(6):e0130393. doi: 10.1371/journal.pone.0130393. eCollection 2015.
3
Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.澳大利亚三阴性乳腺癌中种系 PALB2 突变的低发生率。
Int J Cancer. 2014 Jan 15;134(2):301-5. doi: 10.1002/ijc.28361. Epub 2013 Sep 23.
4
Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis.肿瘤抑制性泛素连接酶Smurf2在三阴性乳腺癌中的下调：RB-微小RNA轴的作用
BMC Cancer. 2014 Feb 3;14:57. doi: 10.1186/1471-2407-14-57.
5
Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.人类乳腺癌中突变型p53的积累并非内在特性，也不依赖于结构或功能破坏，而是受外源性应激和受体状态调控。
J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21.
6
In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.三阴性乳腺癌亚型细胞系中 PIK3CA/mTOR 抑制的体外效应。
Breast Dis. 2022;41(1):241-247. doi: 10.3233/BD-210066.
7
Phenotypic diversity of breast cancer-related mutations in metalloproteinase-disintegrin ADAM12.金属蛋白酶-解聚素 ADAM12 中与乳腺癌相关的突变的表型多样性。
PLoS One. 2014 Mar 20;9(3):e92536. doi: 10.1371/journal.pone.0092536. eCollection 2014.
8
Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.三阴性乳腺癌和PTEN（磷酸酶和张力蛋白同源物）缺失是早发性和家族性乳腺癌女性中BRCA1种系突变的预测指标，但在散发性晚发性乳腺癌女性中并非如此。
Breast Cancer Res. 2012 Nov 2;14(6):R142. doi: 10.1186/bcr3347.
9
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.秘鲁HER2扩增和三阴性非转移性乳腺癌患者中的PIK3CA突变
Hematol Oncol Stem Cell Ther. 2014 Dec;7(4):142-8. doi: 10.1016/j.hemonc.2014.09.007. Epub 2014 Oct 29.
10
The circular RNA circEIF3M promotes breast cancer progression by promoting cyclin D1 expression.环状 RNA circEIF3M 通过促进细胞周期蛋白 D1 的表达促进乳腺癌的进展。
Aging (Albany NY). 2020 Jul 11;12(14):14775-14790. doi: 10.18632/aging.103539.
引用本文的文献
1
Enhancing Photothermal Therapy Against Breast Cancer Cells by Modulating the End Point of Gold Shell-Isolated Nanoparticles Using Nanostraw-Assisted Injection.通过纳米吸管辅助注射调节金壳隔离纳米颗粒的终点来增强对乳腺癌细胞的光热疗法
ACS Appl Mater Interfaces. 2025 May 14;17(19):27816-27828. doi: 10.1021/acsami.5c00084. Epub 2025 Apr 29.
2
PCSK5 is a recessive hypomorph exclusive to MCF10DCIS.com cells.PCSK5是MCF10DCIS.com细胞所特有的隐性亚效等位基因。
bioRxiv. 2025 Mar 7:2025.03.03.641323. doi: 10.1101/2025.03.03.641323.
3
Pharmacological Profiling of and : Unraveling the Antibacterial and Anti-Cancer Potential of Chemically Active Metabolites.[具体物质名称1]和[具体物质名称2]的药理学分析：揭示化学活性代谢物的抗菌和抗癌潜力
J Cancer. 2025 Jan 1;16(1):12-33. doi: 10.7150/jca.96848. eCollection 2025.
4
Syntheses of 3-(2-Nitrovinyl)-indoles, Benzo[]carbazoles, Naphtho[2,1-]carbazoles, and 1-Hydroxy-β-carbolines Lead to Identification of Antiproliferative Compounds Active under Hypoxia.3-(2-硝基亚乙烯基)-吲哚、苯并[ ]咔唑、萘并[2,1-]咔唑和 1-羟基-β-咔啉的合成导致了在缺氧条件下具有抗增殖活性的化合物的鉴定。
J Org Chem. 2024 Oct 4;89(19):13923-13936. doi: 10.1021/acs.joc.4c01028. Epub 2024 Sep 16.
5
Leveraging preclinical models of metastatic breast cancer.利用转移性乳腺癌的临床前模型。
Biochim Biophys Acta Rev Cancer. 2024 Sep;1879(5):189163. doi: 10.1016/j.bbcan.2024.189163. Epub 2024 Jul 29.
6
The LCLAT1/LYCAT acyltransferase is required for EGF-mediated phosphatidylinositol-3,4,5-trisphosphate generation and Akt signaling.LCLAT1/LYCAT酰基转移酶是表皮生长因子介导的磷脂酰肌醇-3,4,5-三磷酸生成和Akt信号传导所必需的。
Mol Biol Cell. 2024 Sep 1;35(9):ar118. doi: 10.1091/mbc.E23-09-0361. Epub 2024 Jul 18.
7
The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer.天然代谢产物在靶向内分泌非依赖性HER-2阴性乳腺癌方面的治疗潜力。
Front Pharmacol. 2024 Mar 4;15:1349242. doi: 10.3389/fphar.2024.1349242. eCollection 2024.
8
Encapsulated Rose Bengal Enhances the Photodynamic Treatment of Triple-Negative Breast Cancer Cells.封装的孟加拉玫瑰红增强三阴性乳腺癌细胞的光动力治疗
Molecules. 2024 Jan 22;29(2):546. doi: 10.3390/molecules29020546.
9
Cellular Plasticity in Mammary Gland Development and Breast Cancer.乳腺发育与乳腺癌中的细胞可塑性
Cancers (Basel). 2023 Nov 27;15(23):5605. doi: 10.3390/cancers15235605.
10
Stromal heterogeneity may explain increased incidence of metaplastic breast cancer in women of African descent.基质异质性可能解释了非裔女性中多形性乳腺癌发病率增加的原因。
Nat Commun. 2023 Sep 14;14(1):5683. doi: 10.1038/s41467-023-41473-6.
本文引用的文献
1
Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.神经纤毛蛋白-1 在 Claudin-低表达乳腺癌中过表达，并通过获得干细胞特征和 RAS/MAPK 通路激活促进肿瘤进展。
Breast Cancer Res. 2022 Jan 25;24(1):8. doi: 10.1186/s13058-022-01501-7.
2
Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells.高转移性 Claudin-low 型乳腺癌可起源于腔上皮细胞。
Nat Commun. 2021 Jun 18;12(1):3742. doi: 10.1038/s41467-021-23957-5.
3
Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution.全面表征 Claudin-low 型乳腺癌肿瘤反映了起始细胞对癌症演化的影响。
Nat Commun. 2020 Jul 9;11(1):3431. doi: 10.1038/s41467-020-17249-7.
4
Re-definition of claudin-low as a breast cancer phenotype.Claudin-low 被重新定义为乳腺癌表型。
Nat Commun. 2020 Apr 14;11(1):1787. doi: 10.1038/s41467-020-15574-5.
5
Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells.条形码揭示了新转化的人类乳腺细胞的复杂克隆动力学。
Nature. 2015 Dec 10;528(7581):267-71. doi: 10.1038/nature15742. Epub 2015 Dec 2.
6
Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes.起源的细胞类型以及基因改变都对乳腺癌表型有影响。
Oncotarget. 2015 Apr 20;6(11):9018-30. doi: 10.18632/oncotarget.3379.
7
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.新辅助化疗后三阴性乳腺癌残留病灶的分子特征分析可确定可采取行动的治疗靶点。
Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19.
8
Comprehensive molecular portraits of human breast tumours.人类乳腺肿瘤的全面分子特征图谱。
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
9
Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening.患有1型神经纤维瘤病的女性患乳腺癌的风险中度增加，应考虑进行早期筛查。
J Med Genet. 2007 Aug;44(8):481-4. doi: 10.1136/jmg.2007.049346. Epub 2007 Mar 16.
10
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.人乳腺癌细胞系中的磷脂酰肌醇-3-羟基激酶或RAS途径突变。
Mol Cancer Res. 2007 Feb;5(2):195-201. doi: 10.1158/1541-7786.MCR-06-0263.
Zotero 插件